The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626001272381
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
26/09/2026
Date registered
Help: Date registered
23/10/2026
Date last updated
Help: Date last updated
23/10/2026
Date data sharing statement initially provided
Help: Data sharing statement date
23/10/2026
Date results provided
Help: Date results provided
23/10/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Looking at Mycobacterium paratuberculosis infection in patients with Crohn's disease and whether there is growth and activity observed in blood testing with changes in the gut flora.
Scientific title
Investigating Mycobacterium avium paratuberculosis Prevalence and Microbiome Dysbiosis in Crohn’s Disease
Additional trial identifiers [1] 318474 0
nil
Universal Trial Number (UTN)
Trial acronym
MAPINCD
Related trial records

Health condition
Health condition(s) studied:
Crohn's disease 343647 0
Condition category
Condition code
Infection 339759 339759 0 0
Studies of infection and infectious agents
Inflammatory and Immune System 339760 339760 0 0
Other inflammatory or immune system disorders

Intervention/exposure
Study type
Observational
Patient registry
True
Target follow-up duration
6
Target follow-up type
Months
Description of the intervention or exposure
BRIEF DESCRIPTION OF EXPOSURE & OBSERVATION

This is a prospective observational study investigating the presence of Mycobacterium avium subspecies paratuberculosis (MAP) in two populations: patients with mild-to-moderate confirmed Crohn's disease (CD, n=30) and disease-free control participants (n=30). The exposures observed are: (1) presence and characterisation of MAP, including morphologically distinct ruptured forms, detected via blood culture microscopy and IS900-targeted sequencing of blood and intestinal biopsy samples; (2) gut microbiome composition and dysbiosis via 16S rRNA sequencing of stool (The Borody Institute). No study treatment is given; all participants receive standard clinical care as determined by their treating clinician.

Duration of observation: CD participants are observed for 24 weeks (Day 0 and Week 24 visits). Control participants are observed at a single visit (Day 0).

ARM 1: CROHN'S DISEASE GROUP (n=30)

Day 0 visit (approximately 3 hours, held on the day of a clinically indicated colonoscopy):
- Standard care: bowel preparation the day before, as for any colonoscopy; pre-procedure review; colonoscopy under sedation (approx. 30-45 minutes) with routine diagnostic biopsies and endoscopic scoring of disease activity; post-procedure recovery (approx. 60 minutes).
- Research procedures: clinical assessment (approx. 20 minutes) covering disease activity (CDAI or Harvey-Bradshaw Index), Montreal classification, current and past medications including immunosuppressants, biologics, antibiotics and prior anti-MAP therapy, and demographics; one additional 10 mL blood sample (approx. 5 minutes); up to 4 additional intestinal biopsies taken during the same colonoscopy (adds approx. 5 minutes); one stool sample collected before bowel preparation.
- Routine bloods (e.g., CRP) and faecal calprotectin results are recorded where collected as part of standard care.

Week 24 visit (approximately 3 hours, held on the day of the standard-of-care follow-up colonoscopy to assess treatment response):
- Standard care: bowel preparation, pre-procedure review, colonoscopy under sedation (approx. 30-45 minutes) with routine biopsies and endoscopic scoring, and post-procedure recovery (approx. 60 minutes).
- Research procedures: follow-up clinical assessment (approx. 15 minutes) covering disease activity, treatment response, changes in therapy, and intercurrent antibiotic use or infection; repeat 10 mL blood sample; up to 4 additional research biopsies; repeat stool sample collected before bowel preparation. Laboratory protocols are identical to Day 0.

Who delivers: gastroenterologists perform colonoscopy and biopsies; the research nurse or delegated research staff conduct the consent taking, clinical assessment and sample collection; accredited laboratories (Otakaro Pathways; The Borody Institute) perform analyses.
Location: Centre for Digestive Diseases, Five Dock, Sydney.

No participant undergoes colonoscopy solely for this study.

Adherence/fidelity: standardised sample collection SOPs; all samples are processed through the same accredited laboratory pipeline; sample timing, storage and protocol deviations are documented; CD participants receive a reminder at Week 20; loss to follow-up and reasons are recorded.
Intervention code [1] 335377 0
Not applicable
Description of the comparator or control

ARM 2: CONTROL GROUP (n=30)

Participants without inflammatory bowel disease or gastrointestinal symptoms who are already scheduled for a clinically indicated colonoscopy (e.g., screening).

Day 0 visit only (approximately 3 hours, held on the day of their scheduled colonoscopy):
- Standard care: bowel preparation, pre-procedure review, colonoscopy under sedation (approx. 30-45 minutes), and post-procedure recovery (approx. 60 minutes).
- Research procedures: clinical assessment (approx. 15 minutes) covering symptoms, comorbidities, medications, antibiotic exposure, prior therapy, and demographics; one additional 10 mL blood sample; up to 4 additional intestinal biopsies during the colonoscopy; one stool sample collected before bowel preparation. Laboratory protocols are identical to the CD arm.
- No follow-up visit.
Control group
Active

Outcomes
Primary outcome [1] 346937 0
Proportion of Crohn’s disease participants with ruptured MAP forms in blood.
Timepoint [1] 346937 0
baseline (Day 0)
Primary outcome [2] 346938 0
Proportion of healthy controls participants with ruptured MAP forms in blood.
Timepoint [2] 346938 0
baseline (Day 0)
Secondary outcome [1] 468183 0
Gut microbiome diversity in Crohn’s disease participants and healthy controls..
Timepoint [1] 468183 0
Day 0 (CD participants and controls) and Week 24 from baseline (CD participants only)
Secondary outcome [2] 468184 0
Change in Crohn’s disease activity in Crohn’s disease participants. This is a composite secondary outcome made up of symptomatic, biochemical, endoscopic components.
Timepoint [2] 468184 0
baseline and 6 months post baseline
Secondary outcome [3] 469185 0
Proportion of MAP-positive Crohn’s disease participants with active disease (CDAI greater than or equal to 150) whose blood culture shows MAP growth.
Timepoint [3] 469185 0
Day 0 and Week 24.
Secondary outcome [4] 469186 0
Change in MAP status in intestinal biopsy (MAP positive to MAP negative, or MAP negative to MAP positive) in CD participants between Day 0 and Week 24.
Timepoint [4] 469186 0
Day 0 and week 24 from baseline in crohn's patients

Eligibility
Key inclusion criteria
• Males and females aged 18 – 75 years
30 patients with a diagnoses of Crohn's Disease
• 30 healthy controls (e.g. no inflammatory bowel disease, no irritable bowel syndrome)
• Provide written informed consent to participate as shown by a signature on the consent form.
Minimum age
18 Years
Maximum age
75 Years
Sex
Both males and females
Healthy volunteers
Yes
Key exclusion criteria
• Consent not obtained.
• Any contraindications for testing e.g. bleeding
• Clinical evidence of any disease which might interfere with the patient’s ability to enter the trial.
Diseases prohibiting eligibility: Participants will be excluded if they have a diagnosis of another significant gastrointestinal inflammatory disorder (e.g. ulcerative colitis, indeterminate colitis, coeliac disease, microscopic colitis), active gastrointestinal infection, known immunodeficiency disorder, active malignancy requiring treatment, or any other medical condition that may confound interpretation of MAP testing or study outcome.

Study design
Purpose
Natural history
Duration
Longitudinal
Selection
Case control
Timing
Prospective
Statistical methods / analysis
Tier 1: Stratified Analysis (Shows the confounder effect)
Tier 2: Multivariable Regression (Adjusts remaining confounders)
Tier 3: Sensitivity Analyses (Robustness checks)

Power Considerations
With n=30 per group:
Crude MAP prevalence (expecting 40% CD vs 10% controls according to prior PCR data): ~70% power to detect OR ˜ 5
Microbiome diversity: Moderate power for moderate effect sizes (R² ˜ 0.10–0.15)
Longitudinal changes (n=27 CD at 6 months): Moderate power for within-subject changes
CIs will be wide and so will have limited precision, but the aim is for exploratory findings to inform whether future larger studies are desirable.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 30237 0
Centre for Digestive Diseases - Five Dock
Recruitment postcode(s) [1] 46636 0
2046 - Five Dock

Funding & Sponsors
Funding source category [1] 323053 0
Hospital
Name [1] 323053 0
Centre for Digestive Diseases
Country [1] 323053 0
Australia
Primary sponsor type
University
Name
University of Western Sydney
Address
Country
Australia
Secondary sponsor category [1] 326176 0
None
Name [1] 326176 0
Address [1] 326176 0
Country [1] 326176 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 321455 0
University of Western Sydney Human Research Ethics Committee
Ethics committee address [1] 321455 0
Ethics committee country [1] 321455 0
Australia
Date submitted for ethics approval [1] 321455 0
04/03/2026
Approval date [1] 321455 0
01/07/2026
Ethics approval number [1] 321455 0
HREC Approval Number: H17222

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 153778 0
Dr Gaurav Agrawal
Address 153778 0
Centre for Digestive Diseases, Level 1, 229 Great North Road, Five Dock ,NSW, Australia 2046
Country 153778 0
Australia
Phone 153778 0
+61431650422
Fax 153778 0
Email 153778 0
Contact person for public queries
Name 153779 0
Holly Matthews
Address 153779 0
Centre for Digestive Diseasesm Lvl 1 229 Great North Rd, Five Dock, NSW, 2046
Country 153779 0
Australia
Phone 153779 0
+61297134011
Fax 153779 0
Email 153779 0
Contact person for scientific queries
Name 153780 0
Siba Dolai
Address 153780 0
Centre for Digestive Diseases Lvl 1 229 Great North Rd, Five Dock, NSW, 2046
Country 153780 0
Australia
Phone 153780 0
+61297134011
Fax 153780 0
Email 153780 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
TypeIs Peer Reviewed?DOICitations or Other DetailsAttachment
ProtocolNo MAP_Study_Protocol_v1.1_CLEAN.docx
Statistical analysis planNo MAP_Statistical_Analysis_Plan.docx
Plain language summaryNo MAP_Lay_Summary_Results.docx
Study results articleNo MAP_Journal_Publications_Plan.docx

Documents added automatically
No additional documents have been identified.